ASX Announcements

Date Part Topic
27 April 2011   Market update
23 February 2011   Half year accounts
23 February 2011   Lapse of unlisted bonus options
23 February 2011   Appendix 4D
10 January 2011   Profit guidance and business update
10 January 2011   Appointment of new director
04 November 2010   Results of meeting
04 November 2010   Managing Director's Powerpoint Presentation
04 November 2010   Chairman & Managing Director's Address at AGM
27 September 2010   Annual Report
27 September 2010   Notice of Meeting and Proxy Form
01 September 2010   Preliminary Final report
30 April 2010   Change of Directors Interest Notice (x6)
30 April 2010   Confirmation of Allotment of Bonus Options
14 April 2010   Bonus Option Offer Prospectus
12 April 2010   ASX Release
06 April 2010   Appendix 3B
06 April 2010   Response to a ASX Price Query
05 March 2010   SandP Announces March SP/ASX Index Rebalance
18 February 2010   Appendix 3B
16 February 2010   Half Yearly Reports and Accounts
30 October 2009   Managing Director Powerpoint Presentation
30 October 2009   Chairman`s and Managing Directors Address at AGM
30 October 2009   Results of meeting
29 September 2009   Annual Report
29 September 2009   Notice of Meeting and Proxy Form
18th August 2009   Preliminary Final Report
29 April 2009   Change of Director's Interest Notice
06 March 2009   SandP Announces March SP/ASX Index Rebalance
17 February 2009   Half Yearly Report and Accounts
23 December 2008   Market update
31 October 2008   Results of meeting
31 October 2008   Chairman's address to Shareholders
14 October 2008   Change of Director`s Interest Notice
14 October 2008   Change in substantial holding
13 October 2008   Ceasing to be a substantial holder from ANZ
30 September 2008   Notice of Annual General Meeting
30 September 2008   Proxy Form
30 September 2008   Annual Report
03 September 2008   Change of Director's Interest Notice
01 September 2008   Change of Director`s Interest Notice
28 August 2008   Change in substantial holding
15 August 2008   Preliminary final report
11 August 2008   IDT Facility Opening
21 July 2008   Change in substantial holding
21 July 2008   Change of Director's Interest Notice
9 July 2008   Response to an ASX Query re Margin Lending Facilities
8 July 2008   ANZ: Primebroker Disclosure
8 July 2008   Trading Halt Request
12 May 2008   Form 603 and 604 from ANZ
19 February 2008   Half Yearly Report and Accounts
02 January 2008   Initial Director's Interest Notice
26 October 2007   Constitution
26 October 2007   Results of Meeting
26 October 2007   Chairman's Address to Shareholders
26 October 2007   Chairman's Address to Shareholders
11 October 2007   Reply to ASX Price Query
24 September 2007   Notice of Annual General Meeting
24 September 2007   Proxy Form
24 September 2007   Annual Report
14 August 2007   Preliminary final report
6 August 2007   Appendix 3B - New Issue Announcement
20 February 2007   Half Yearly Report & Half Yearly Accounts
25 January 2007   IDT Expands Drug Development Relationship with Pfizer
12 December 2006   Response to ASX Query re Share Price
27 October 2006   Final Director's Interest Notice
27 October 2006   AGM Meeting
27 October 2006   AGM Chairman Presentation
27 October 2006   AGM Chairman Presentation
27 September 2006   Retirement of Director
26 September 2006   Notice of Annual General Meeting
26 September 2006   Proxy Form
26 September 2006   Annual Report
22 August 2006   Change of Directors Interest Notice
16 August 2006   Appendix 3B - New Issue Announcement
15 August 2006   Preliminary final report
07 June2006   Change of Director's Interest Notice 2
31 May 2006   Change of Director's Interest Notice 2
30 May 2006   Change of Director's Interest Notice 2
23 February 2006   Half Yearly Report & Half Yearly Accounts
27 January 2006   Change of Director's Interest
17 February 2006   Ceasing to be a substantial holder from AMP
24 January 2006   Change of Director's Interest
  • Cytotoxic Active Pharmaceutical Ingredients (API's)
  • High Potency API's
  • Hormones
  • Toxic Reagents
  • API Manufacture
  • New Drug Development and Scale-up
  • Clinical Research Services
  • Pharmacy Services